Gossamer Bio (GOSS) Stock Forecast, Price Target & Predictions
GOSS Stock Forecast
Gossamer Bio stock forecast is as follows: an average price target of $3.75 (represents a 306.99% upside from GOSS’s last price of $0.92) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
GOSS Price Target
The average price target for Gossamer Bio (GOSS) is $3.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential 306.99% upside from GOSS's last price of $0.92.
GOSS Analyst Ratings
According to 12 Wall Street analysts, Gossamer Bio's rating consensus is 'Buy'. The analyst rating breakdown for GOSS stock is 0 'Strong Buy' (0.00%), 8 'Buy' (66.67%), 4 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Gossamer Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | H.C. Wainwright | $5.00 | $2.16 | 131.48% | 442.65% |
| Dec 07, 2022 | - | Barclays | $2.00 | $2.36 | -15.25% | 117.06% |
| Dec 07, 2022 | - | Raymond James | $5.00 | $2.36 | 111.86% | 442.65% |
| Dec 06, 2022 | David Hoang | SMBC Nikko | $3.00 | $2.36 | 27.12% | 225.59% |
| Apr 26, 2022 | - | Barclays | $12.00 | $8.45 | 42.01% | 1202.37% |
| Apr 26, 2022 | - | Raymond James | $10.00 | $9.08 | 10.13% | 985.30% |
The latest Gossamer Bio stock forecast, released on Dec 08, 2022 by H.C. Wainwright company, set a price target of $5.00, which represents a 131.48% increase from the stock price at the time of the forecast ($2.16), and a 442.65% increase from GOSS last price ($0.92).
Gossamer Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.92 | $0.92 | $0.92 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Gossamer Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Gossamer Bio's last price of $0.92. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 24, 2024 | Oppenheimer | Buy | Outperform | Initialise |
| May 06, 2024 | Guggenheim | - | Positive | Initialise |
| May 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 06, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Mar 07, 2023 | Raymond James | Outperform | Market Perform | Downgrade |
| Dec 08, 2022 | Oppenheimer | Buy | Buy | Hold |
| Dec 07, 2022 | Goldman Sachs | Buy | Buy | Hold |
| Dec 07, 2022 | UBS | Buy | Buy | Hold |
| Dec 07, 2022 | Barclays | Overweight | Equal-Weight | Downgrade |
Gossamer Bio's last stock rating was published by Piper Sandler on Sep 12, 2024. The company gave GOSS a "Overweight" rating, the same as its previous rate.
Gossamer Bio Financial Forecast
Gossamer Bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $95.84M | $95.84M | $95.84M | $95.84M | $10.57M | $3.27M | $3.64M | $3.64M | $8.54M | $8.53M | $114.29M | - | - |
| High Forecast | $95.84M | $95.84M | $95.84M | $95.84M | $10.57M | $3.27M | $3.64M | $3.64M | $8.54M | $16.04M | $114.29M | - | - |
| Low Forecast | $95.84M | $95.84M | $95.84M | $95.84M | $10.57M | $3.27M | $3.64M | $3.64M | $8.54M | $2.00M | $114.29M | - | - |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GOSS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Gossamer Bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict GOSS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Gossamer Bio's previous annual EBITDA (undefined) of $NaN.
Gossamer Bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-42.70M | $-42.72M | $-42.75M | $-42.79M | $-38.95M | $-45.41M | $-45.21M | $-45.65M | $-34.68M | $-35.10M | $120.86M | $-42.91M | $-46.96M |
| High Forecast | $-42.70M | $-42.72M | $-42.75M | $-42.79M | $-38.95M | $-45.41M | $-45.21M | $-45.65M | $-34.68M | $-23.40M | $120.86M | $-42.91M | $-39.92M |
| Low Forecast | $-42.70M | $-42.72M | $-42.75M | $-42.79M | $-38.95M | $-45.41M | $-45.21M | $-45.65M | $-34.68M | $-40.96M | $120.86M | $-42.91M | $-56.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GOSS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Gossamer Bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gossamer Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GOSS last annual SG&A of $NaN (undefined).
Gossamer Bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.16 | $-0.19 | $-0.19 | $-0.19 | $-0.15 | $-0.15 | $0.51 | $-0.19 | $-0.21 |
| High Forecast | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.16 | $-0.19 | $-0.19 | $-0.19 | $-0.15 | $-0.10 | $0.51 | $-0.19 | $-0.18 |
| Low Forecast | $-0.18 | $-0.18 | $-0.18 | $-0.18 | $-0.16 | $-0.19 | $-0.19 | $-0.19 | $-0.15 | $-0.17 | $0.51 | $-0.19 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Gossamer Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GOSS previous annual EPS of $NaN (undefined).
Gossamer Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| FDMT | 4D Molecular Therapeutics | $16.25 | $44.57 | 174.28% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
GOSS Forecast FAQ
Is Gossamer Bio a good buy?
Yes, according to 12 Wall Street analysts, Gossamer Bio (GOSS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 66.67% of GOSS's total ratings.
What is GOSS's price target?
Gossamer Bio (GOSS) average price target is $3.75 with a range of $2 to $5, implying a 306.99% from its last price of $0.921. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gossamer Bio stock go up soon?
According to Wall Street analysts' prediction for GOSS stock, the company can go up by 306.99% (from the last price of $0.921 to the average price target of $3.75), up by 442.65% based on the highest stock price target, and up by 117.06% based on the lowest stock price target.
Can Gossamer Bio stock reach $1?
GOSS's average twelve months analyst stock price target of $3.75 supports the claim that Gossamer Bio can reach $1 in the near future.
What are Gossamer Bio's analysts' financial forecasts?
Gossamer Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $21.13M (high $21.13M, low $21.13M), average EBITDA is $0 (high $0, low $0), average net income is $-175M (high $-175M, low $-175M), average SG&A $0 (high $0, low $0), and average EPS is $-0.735 (high $-0.735, low $-0.735). GOSS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $383.37M (high $383.37M, low $383.37M), average EBITDA is $0 (high $0, low $0), average net income is $-171M (high $-171M, low $-171M), average SG&A $0 (high $0, low $0), and average EPS is $-0.717 (high $-0.717, low $-0.717).